$ATNM News

Actinium Presents New ATNM-400 Data in KRAS and EGFR Mutant Models at SNMMI 2026 Supporting a Mutation-Agnostic Opportunity In Non-Small Cell Lung Cancer

Actinium Pharmaceuticals Oral Presentation at SNMMI 2026 Highlights ATNM-400 Overcoming Resistance to All Three Approved Androgen Receptor Inhibitors and Offers Flexible, Well-Tolerated Dosing in Prostate Cancer Models

Actinium's ATNM-400 Reports Preclinical Activity And Combination Synergy Across KRAS- And EGFR-Mutant NSCLC, Supporting Mutation-Agnostic Potential

Actinium Pharma Presents New Data On ATNM-400 In Prostate Cancer At SNMMI 2026 Annual Meeting

Actinium Appoints Accomplished Oncology Expert Steffen Heeger MD, MSc as Chief Medical Officer to Drive Rejuvenated Pipeline Development

Actinium Pharmaceuticals Presents New Radiochemistry Data at SNMMI 2026 Demonstrating That CAR Optimization Improves Tumor Targeting and Pharmacokinetics of Actinium-225 Radioconjugates

Actinium Pharmaceuticals Receives Two Patent Allowances Spanning Its Actimab-A and Iomab-ACT Programs

Actinium Pharmaceuticals to Present ATNM-400 Program Update at SNMMI 2026 Conference on May 31-June 2 and Provides NYSE American Listing Standards Notice

Actinium Pharmaceuticals Obtains Two Patent Allowances Spanning Its Actimab-A And Iomab-ACT Programs

Actinium Pharmaceuticals To Reveal ATNM-400 Program Update At SNMMI 2026 Conference on May 31-June 2; Co. Receives NYSE Noncompliance Notice

Actinium Pharmaceuticals Announces Three SNMMI 2026 Presentations Highlighting Differentiated Profile of ATNM-400 Across Lung and Prostate Cancer and Radioconjugate Optimization

Actinium Highlights Transcriptional Reprogramming as a Key Mechanism Underpinning Mutation-Agnostic Activity of Actimab-A in AML at the 2026 American Association of Cancer Research Annual Meeting

Actinium Pharmaceuticals, Inc. Announces Compelling Pan-Tumor Data for ATNM-400 Demonstrating Broad Efficacy Across Prostate, Lung, and Breast Cancer Models at the 2026 American Association of Cancer Research Annual Meeting

Actinium Highlights Data Presented At AACR Supporting Transcriptional Reprogramming As Central Mechanism Driving Mutation-Agnostic Anti-Leukemic Activity Of Actimab-A In AML

Actinium Pharma Presents Preclinical Results For ATNM-400 Across Prostate, Lung, And Breast Cancer Models Presented At AACR Annual Meeting

Actinium Pharmaceuticals Announces New Pan-Tumor Preclinical Data for ATNM-400 in Solid Tumors and Differentiated Mechanism for Actimab-A in AML to be Presented at 2026 AACR Annual Meeting

Actinium Pharmaceuticals shares are trading higher after the company announced that two abstracts, on ATNM-400 and Actimab-A, respectively, will be presented at the American Association for Cancer Research Annual Meeting 2026 on April 17-22, 2026.

Actinium Pharmaceuticals shares are trading higher after the company announced that two abstracts, on ATNM-400 and Actimab-A, respectively, will be presented at the American Association for Cancer Research Annual Meeting 2026 on April 17-22, 2026.

Actinium Pharmaceuticals Announces New Pan-Tumor Data Demonstrating Potential Of Its Ac-225 Radiotherapy Platform Across Solid Tumors And Hematologic Malignancies; Data To Be Presented At AACR Annual Meeting On April 21

Stephens & Co. Reiterates Overweight on Actinium Pharma, Maintains $5 Price Target